Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: A large, confirmatory trial

Blood Pressure Monitoring

Volumn 13, Issue 1, 2008, Pages 21-27

  White, William B ^a   Murwin, Debra ^b   Chrysant, Steven G ^c   Koval, Stephen E ^b   Davidai, Giora ^b   Guthrie, Robert ^d  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Confirmatory antihypertensive clinical trial; Fixed dose combination therapy; Telmisartan; Thiazide diuretics; Valsartan

Indexed keywords

HYDROCHLOROTHIAZIDE; PLACEBO; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANXIETY; ARTICLE; BACKACHE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ETHNICITY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; PRIORITY JOURNAL; RHINOPHARYNGITIS; SEX DIFFERENCE; SIDE EFFECT; SINUSITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 38349042145     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBP.0b013e3282f3859d     Document Type: Article

References (27)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 60 prospective studies. Lancet 2002; 14:1903-1913.
2. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351:1755-1762.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high BP. JAMA 2003; 289:2560-2572.
4. European Society of Hypertension-European Society of Cardiology Guidelines Committee. J Hypertens 2003; 21:1011-1054.
5. Ruddy MC, Kostis JB. Angiotensin receptor antagonists. In: Oparil S, Weber MA, editors. Hypertension. Philadelphia: WB Saunders Co.; 2000. pp. 621-637.
6. McGill JB, Rilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled parallel-group trial. Clin Ther 2001; 23:833-850.
7. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenelol. Lancet 2002; 359:995-1003.
8. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363:2049-2051.
9. Cohn JN, Tognoni G; for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
10. Brenner BM, Cooper ME, deZeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:51-60.
12. Moser M. Update on the management of hypertension: recent clinical trials and the JNC 7. J Clin Hypertens 2004; 6:4-13.
13. White WB, Punzi H, Murwin D, Koval SE, Davidai G, Neutel JM. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide 25mg once daily in the treatment of hypertension. J Clin Hypertens 2006; 8:626-633.
14. Medical Dictionary for Regulatory Activities Terminology (MedDRA): Version 3.3, Reston, VA, MedDRA MSSO, December 2000.
15. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Am J Hypertens 2004; 17:347-353.
16. Giles TD, Bakris GL, Smith DHG, Davidai G, Weber MA. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens 2003; 16:460-466.
17. Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9:203-210.
18. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12:861-866.
19. Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gleim GW, Oparil S. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005; 5:17-22.
20. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs 2002; 62:787-816.
21. Neutel JM, Kolloch RE, Plouin PF, Meinicke TW, Schumacher H. Telmisartan versus losartan plus hydrochlorothiazide in the treatment of mild-tomoderate essential hypertension - a randomized ABPM study. J Hum Hypertens 2003; 17:569-575.
22. Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of the antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17:252-259.
23. Vidt DG, White WB, Ridley E, Rahman M, Harris S, Vendetti J, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15:471-480.
24. Calvo C, Hermida RC, Ayala DE, Ruilope L. Effects of telmisartan 80mg and valsartan 160mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22:837-846.
25. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155:701-709.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
27. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al.; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.